Literature DB >> 25485901

Temporal and gefitinib-sensitive regulation of cardiac cytokine expression via chronic β-adrenergic receptor stimulation.

Laurel A Grisanti1, Ashley A Repas1, Jennifer A Talarico2, Jessica I Gold2, Rhonda L Carter1, Walter J Koch1, Douglas G Tilley3.   

Abstract

Chronic stimulation of β-adrenergic receptors (βAR) can promote survival signaling via transactivation of epidermal growth factor receptor (EGFR) but ultimately alters cardiac structure and contractility over time, in part via enhanced cytokine signaling. We hypothesized that chronic catecholamine signaling will have a temporal impact on cardiac transcript expression in vivo, in particular cytokines, and that EGFR transactivation plays a role in this process. C57BL/6 mice underwent infusion with vehicle or isoproterenol (Isogefitinib (Gef) for 1 or 2 wk. Cardiac contractility decreased following 2 wk of Iso treatment, while cardiac hypertrophy, fibrosis, and apoptosis were enhanced at both timepoints. Inclusion of Gef preserved contractility, blocked Iso-induced apoptosis, and prevented hypertrophy at the 2-wk timepoint, but caused fibrosis on its own. RNAseq analysis revealed hundreds of cardiac transcripts altered by Iso at each timepoint with subsequent RT-quantitative PCR validation confirming distinct temporal patterns of transcript regulation, including those involved in cardiac remodeling and survival signaling, as well as numerous cytokines. Although Gef infusion alone did not significantly alter cytokine expression, it abrogated the Iso-mediated changes in a majority of the βAR-sensitive cytokines, including CCL2 and TNF-α. Additionally, the impact of βAR-dependent EGFR transactivation on the acute regulation of cytokine transcript expression was assessed in isolated cardiomyocytes and in cardiac fibroblasts, where the majority of Iso-dependent, and EGFR-sensitive, changes in cytokines occurred. Overall, coincident with changes in cardiac structure and contractility, βAR stimulation dynamically alters cardiac transcript expression over time, including numerous cytokines that are regulated via EGFR-dependent signaling.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  EGFR; cytokines; heart; remodeling; βAR

Mesh:

Substances:

Year:  2014        PMID: 25485901      PMCID: PMC4329485          DOI: 10.1152/ajpheart.00635.2014

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  49 in total

1.  Open source clustering software.

Authors:  M J L de Hoon; S Imoto; J Nolan; S Miyano
Journal:  Bioinformatics       Date:  2004-02-10       Impact factor: 6.937

2.  Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.

Authors:  Tanusree Paul; Christian Schumann; Stefan Rüdiger; Stefan Boeck; Volker Heinemann; Volker Kächele; Michael Steffens; Catharina Scholl; Vivien Hichert; Thomas Seufferlein; Julia Carolin Stingl
Journal:  Eur J Cancer       Date:  2014-05-23       Impact factor: 9.162

Review 3.  Expression of the genes of interferons and other cytokines in normal and diseased tissues of man.

Authors:  M G Tovey
Journal:  Experientia       Date:  1989-06-15

4.  Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy.

Authors:  Y Y Li; Y Q Feng; T Kadokami; C F McTiernan; R Draviam; S C Watkins; A M Feldman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

5.  Gene expression profiling: classification of mice with left ventricle systolic dysfunction using microarray analysis.

Authors:  Jim Wong; Christine Chang; Rani Agrawal; G Brant Walton; Craig Chen; Ashwin Murthy; Andrew J Patterson
Journal:  Crit Care Med       Date:  2010-01       Impact factor: 7.598

6.  Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation.

Authors:  Francesca Mascia; Valentina Mariani; Giampiero Girolomoni; Saveria Pastore
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

Review 7.  MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy.

Authors:  Ying Xia; Nikolaos G Frangogiannis
Journal:  Inflamm Allergy Drug Targets       Date:  2007-06

8.  Doxycycline attenuates isoproterenol- and transverse aortic banding-induced cardiac hypertrophy in mice.

Authors:  Mounir Errami; Cristi L Galindo; Amina T Tassa; John M Dimaio; Joseph A Hill; Harold R Garner
Journal:  J Pharmacol Exp Ther       Date:  2007-12-18       Impact factor: 4.030

9.  Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure.

Authors:  Cristi L Galindo; Michael A Skinner; Mounir Errami; L Danielle Olson; David A Watson; Jing Li; John F McCormick; Lauren J McIver; Neil M Kumar; Thinh Q Pham; Harold R Garner
Journal:  BMC Physiol       Date:  2009-12-09

10.  Epidermal EGFR controls cutaneous host defense and prevents inflammation.

Authors:  Beate M Lichtenberger; Peter A Gerber; Martin Holcmann; Bettina A Buhren; Nicole Amberg; Viktoria Smolle; Holger Schrumpf; Edwin Boelke; Parinaz Ansari; Colin Mackenzie; Andreas Wollenberg; Andreas Kislat; Jens W Fischer; Katharina Röck; Jürgen Harder; Jens M Schröder; Bernhard Homey; Maria Sibilia
Journal:  Sci Transl Med       Date:  2013-08-21       Impact factor: 17.956

View more
  14 in total

Review 1.  Protective transcriptional mechanisms in cardiomyocytes and cardiac fibroblasts.

Authors:  Cameron S Brand; Janet K Lighthouse; Michael A Trembley
Journal:  J Mol Cell Cardiol       Date:  2019-04-28       Impact factor: 5.000

Review 2.  Cardiac GPCR-Mediated EGFR Transactivation: Impact and Therapeutic Implications.

Authors:  Laurel A Grisanti; Shuchi Guo; Douglas G Tilley
Journal:  J Cardiovasc Pharmacol       Date:  2017-07       Impact factor: 3.105

3.  Orphan Nuclear Receptor Nur77 Inhibits Cardiac Hypertrophic Response to Beta-Adrenergic Stimulation.

Authors:  Guijun Yan; Ni Zhu; Shengdong Huang; Bing Yi; Xiying Shang; Ming Chen; Nadan Wang; Guan-xin Zhang; Jennifer A Talarico; Douglas G Tilley; Erhe Gao; Jianxin Sun
Journal:  Mol Cell Biol       Date:  2015-07-20       Impact factor: 4.272

4.  Immune cell β2-adrenergic receptors contribute to the development of heart failure.

Authors:  Miles A Tanner; Charles A Maitz; Laurel A Grisanti
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-08-20       Impact factor: 5.125

5.  Role of epidermal growth factor receptor and endoplasmic reticulum stress in vascular remodeling induced by angiotensin II.

Authors:  Takehiko Takayanagi; Tatsuo Kawai; Steven J Forrester; Takashi Obama; Toshiyuki Tsuji; Yamato Fukuda; Katherine J Elliott; Douglas G Tilley; Robin L Davisson; Joon-Young Park; Satoru Eguchi
Journal:  Hypertension       Date:  2015-04-27       Impact factor: 10.190

6.  Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System.

Authors:  Steven J Forrester; Tatsuo Kawai; Shannon O'Brien; Walter Thomas; Raymond C Harris; Satoru Eguchi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-11-09       Impact factor: 13.820

Review 7.  Tumor Necrosis Factor-α in Heart Failure: an Updated Review.

Authors:  Sarah M Schumacher; Sathyamangla V Naga Prasad
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

Review 8.  Proinflammatory Cytokines Mediate GPCR Dysfunction.

Authors:  Maradumane L Mohan; Neelakantan T Vasudevan; Sathyamangla V Naga Prasad
Journal:  J Cardiovasc Pharmacol       Date:  2017-08       Impact factor: 3.105

9.  Epidermal growth factor receptor-dependent maintenance of cardiac contractility.

Authors:  Shuchi Guo; Ama Dedo Okyere; Erin McEachern; Joshua L Strong; Rhonda L Carter; Viren C Patwa; Toby P Thomas; Melissa Landy; Jianliang Song; Ana Maria Lucchese; Thomas G Martin; Erhe Gao; Sudarsan Rajan; Jonathan A Kirk; Walter J Koch; Joseph Y Cheung; Douglas G Tilley
Journal:  Cardiovasc Res       Date:  2022-03-25       Impact factor: 13.081

10.  Imatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model.

Authors:  Le-Xun Wang; Xiao Yang; Yuan Yue; Tian Fan; Jian Hou; Guang-Xian Chen; Meng-Ya Liang; Zhong-Kai Wu
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.